Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Patent ductus arteriosus is a persistent vascular connection between the pulmonary artery and the aorta that normally closes after birth as fetal circulation changes. Its persistence after birth (PDA) is one of the most common congenital heart defects, particularly in premature infants, and can result in abnormal circulation leading to heart failure, pulmonary hypertension, and other complications. Management includes medical therapy with cyclooxygenase inhibitors (such as indomethacin or ibuprofen lysine) or procedural/surgical closure when necessary. This entry, as stated, is not a canonical molecular drug target (such as a receptor or enzyme) but an anatomical lesion corrected physically or physiologically. If a molecular or receptor target is intended, the name should be revised to reflect a specific protein or biomarker associated with the physiology or pathology of the ductus arteriosus.
Cyclooxygenase inhibition (reduces prostaglandins to promote closure of the ductus)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Patent ductus arteriosus anatomical channel (PDA).